Announced ITF 26 September: Mydecine Innovations Group, a biotech and life sciences company that is building an R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems, intends to join the Access Segment of the AQSE Growth Market. Admission expected on 10 October..
DSW Capital 56.5p £12.4m (DSW.L)
The profitable, mid-market, challenger professional services licence network and owner of the Dow Schofield Watts brand, announces that it has supported DSW Tax Advisory's acquisition of STS Europe Ltd (STS) to bring new, complementary capabilities to the business. STS advises clients, including UK-resident non-domiciles, on matters such as inheritance tax, trusts and offshore structures, and also assists offshore banks and trust companies throughout Europe with UK tax issues and is one of the leading firms of its type in the North. The acquisition of STS takes DSW's total Fee Earners to 105, operating from 10 locations across the UK.
Eden Research 4.75p £19.2m (EDEN.L)
The company focused on sustainable biopesticides and plastic-free formulation technology for use in the global crop protection, animal health and consumer products industries, announces its interim results for the six months ended 30 June 2023. Revenue for the period was £1.14m, up 10% (H1 2022: £1.04m). Loss before taxation was £6.19m primarily due to an impairment of intangible assets for £4.97m. Cash and cash equivalents at 31 August 2023 were £1.73m following a tax refund and proceeds from the unconditional placing. The Company continues to expanding regulatory approvals in key territories and new product areas and is on track to meet 2023 market expectations for product sales revenue and EBITDA.
i(x) Net Zero 22.5p £19.3m (IX..L)
The investing company focusing on energy transition, announces its half year results for the six months ended 30 June 2023. Portfolio NAV increased by 133.56% to $149.11m (31 December 2022: $63.84m), largely driven by WasteFuel Global Inc. investment from BP. Profit before non-cash deferred tax provision and share-based compensation was $81.05m (H1 2022: $0.50m). During the period, i(x) made portfolio investments of $0.55m (H1 2022: $0.50m). As at 30 June 2023, the Company had $0.8m borrowings and cash of $4.35m (31 December 2022: no borrowings and cash of $7.48m. The Company has set a near term target of reducing operating expenditure to 2% of NAV, down more than 50% from the 2022 level.
Kibo Energy* 0.055p £2.1m (KIBO.L)
The renewable energy-focused development company announces its unaudited interim results for the six months ended 30 June 2023. Consolidated revenue was £198k, down 35% (1H22: £305k). Operating loss was £1.9m (1H22: 1.8m loss). Cash balance was £22k (December 31, 2022: £164k). In July 2023, Mast Energy Developments (MED) finalised and entered into a definitive and binding Joint Venture Agreement (JVA) with an institutional investor-led consortium, with an initial expected total investment value of c. £5.9m. The completion date of the JVA has since been extended twice due to unforeseen circumstances as detailed in an MED RNS dated 4 August and 22 September 2023. Kibo continues to acquire and develop a portfolio of renewable energy assets and to pursue appropriate disposal and divestment or repurposing of all hydrocarbon and coal-based power projects and assets.
Jade Road Investments* 1.875p £6.7m (JADE.L)
The London quoted pan-Asian diversified investment vehicle announces its interim results for the six months ended 30 June 2023. Total income decreased to US$0.59m and was derived from interest income from investees (H1 2022: US$1.56m). Consolidated NAV at 30 June 2023 increased by 3% to US$ 15.46m/GBP 12.69m. Period end cash position of US$ 0.1m. Post period end, the Company raised gross proceeds of $1.05m in September 2023. The Company continues its transition in investment strategy as it moves away from its previous focus on Asia to a more geographically diverse investment strategy characterised by investing in a portfolio of high yielding assets with a low correlation to most markets or major asset classes.
MobilityOne 5p £5.3m (MBO.L)
The e-commerce infrastructure payment solutions and platform provider, announces its unaudited interim results for the six months ended 30 June 2023. Revenue increased by 7.2% to £121.5m (H1 2022: £113.4m) due to higher sales for the Group's mobile phone prepaid airtime reload and bill payment business in Malaysia. Profit after tax was £5,117 (H1 2022: profit after tax of £0.34m). Cash and cash equivalents (including fixed deposits) at 30 June 2023 was £3.42m (30 June 2022: £4.72m). The Group is cautious on the outlook for the remainder of 2023, taking into consideration rising interest rates and expenses and lower gross profit margins for the Group's products and services.
MS International 730p £119.2m (MSI.L)
The UK-based company engaged in designing, manufacturing, construction and servicing of a range of engineering products and structures announces that a first production and supply contract has been awarded by the United States Navy to its wholly owned subsidiary company, MSI-Defence Systems US LLCbased in Rock Hill, South Carolina, USA. This first contract is for $23.5m and is for the supply of US Navy Mk38 MOD4 gun mounts (which is the US Navy nomenclature for our MSI-DS 30mm gun mounts). Delivery of all equipment is for no later than 18 December 2024.
One Heritage Group* 21p £8.1m (OHG.L)
The UK-based residential developer, development manager and property manager focused on the North of England, announces that Anthony Unsworth has informed the Board of his decision to resign as Chief Financial Officer (CFO) and Executive Director of the Company. Anthony will continue in his role as CFO and Executive Director during his notice period during the next six months. The Board extends its gratitude to Anthony for his dedication and commitment to the Group during his fourteen-month tenure. The Company has started the process of finding the right person for the next leg of the growth in the business.
Provexis 0.58p £12.8m (PXS.L)
The business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, announces its audited results for the year ended 31 March 2023 (FY23). Revenue was £390k, down 8.5% (FY22: £426k). Underlying operating loss for the year was £347k (FY22: £173k in loss). Cash was £379k at 31 March 2023 (FY22: £864k), following inventory purchases in the year of more than £315k. The Company expects that the new gut microbiome patent application, the significant changes to the sales and supply chain structure for Fruitflow from January 2023, and the recent BYHEALTH regulatory developments in China, will have a strongly beneficial effect on the current and future commercial prospects for Fruitflow.
Roebuck Food Group 13.5p £4.1m (RFG.L)
The warehousing company serving the food manufacturing, distribution, and retailing sectors, announce its interim results for the six months ended 30 June 2023. Revenue increased by 19%, from £12.5m in 1H22 to £14.9m in 1H23. Net debt decreased by 32% from £3.4m December 2022 to £2.3m. Both business units (Sourcing and Dairy) profitable, albeit down on prior year. Loss before tax of £0.4m, compared to a profit of £0.2m in 1H22. Management is actively looking at a number of acquisitions and expects to complete at least one of these before the end of the year.
Disclaimer
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@chrish351.sg-host.com with “unsubscribe me”.
